Evidence map›Paper›PMID 38074768›Full record

ArticleFrontiers in public health2023

FAIR+E pathogen data for surveillance and research: lessons from COVID-19.

Aitana Neves, Isabel Cuesta, Erik Hjerde, Terje Klemetsen, David Salgado, Jacques van Helden, Nadim Rahman, Nazeefa Fatima, Nestoras Karathanasis, Pawel Zmora and 4 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Methods for safely sharing dual-use genetic data.Frontiers in microbiology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aitana Neves *SIB Swiss Institute of Bioinformatics, Clinical Bioinformatics, Geneva, Switzerland.
Isabel Cuesta *Bioinformatics Unit, Institute of Health Carlos III, Madrid, Spain.
Erik Hjerde *Institute of Chemistry, The Arctic University of Norway, Tromsø, Norway.
Terje KlemetsenInstitute of Chemistry, The Arctic University of Norway, Tromsø, Norway.
David SalgadoCNRS, Institut Français de Bioinformatique, IFB-core, UMS 3601, Evry, France.
Jacques van HeldenCNRS, Institut Français de Bioinformatique, IFB-core, UMS 3601, Evry, France.
Nadim RahmanEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Nazeefa FatimaELIXIR Norway, Centre for Bioinformatics, University of Oslo, Oslo, Norway.
Nestoras KarathanasisBioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Pawel ZmoraDepartment of Molecular Virology, Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznan, Poland.
Wolmar Nyberg ÅkerströmNBIS National Bioinformatics Infrastructure Sweden, SciLifeLab, Uppsala University, Uppsala, Sweden.
Sushma Nagaraja GrellscheidELIXIR Norway, Department of Informatics, University of Bergen, Bergen, Norway.
Zahra WaheedEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Niklas BlombergELIXIR Hub, Wellcome Genome Campus, Cambridge, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has exemplified the importance of interoperable and equitable data sharing for global surveillance and to support research. While many challenges could be overcome, at least in some countries, many hurdles within the organizational, scientific, technical and cultural realms still remain to be tackled to be prepared for future threats. We propose to (i) continue supporting global efforts that have proven to be efficient and trustworthy toward addressing challenges in pathogen molecular data sharing; (ii) establish a distributed network of Pathogen Data Platforms to (a) ensure high quality data, metadata standardization and data analysis, (b) perform data brokering on behalf of data providers both for research and surveillance, (c) foster capacity building and continuous improvements, also for pandemic preparedness; (iii) establish an International One Health Pathogens Portal, connecting pathogen data isolated from various sources (human, animal, food, environment), in a truly One Health approach and following FAIR principles. To address these challenging endeavors, we have started an ELIXIR Focus Group where we invite all interested experts to join in a concerted, expert-driven effort toward sustaining and ensuring high-quality data for global surveillance and research.

Indexed as

COVID-19AnimalsCapacity BuildingHumansInformation DisseminationPandemicsCOVID-19data sharing and re-useequityFAIR (Findable Accessible Interoperable and Reusable) principlessurveillance

Identifiers

PMID38074768
PMCPMC10703184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.